ArticleInternational journal of molecular sciences2019

Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).

Ruriko Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.